Macrocyclic quinoxaline compounds as HCV NS3 protease...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C540S457000

Reexamination Certificate

active

07973040

ABSTRACT:
The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.

REFERENCES:
patent: 3480613 (1969-11-01), Walton
patent: 6323180 (2001-11-01), Llinas-Brunet et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 6955174 (2005-10-01), Friedrichs et al.
patent: 7470664 (2008-12-01), Holloway et al.
patent: 2002/0019363 (2002-02-01), Ismaili et al.
patent: 2002/0107138 (2002-08-01), Hoveyda et al.
patent: 2003/0236216 (2003-12-01), Devos et al.
patent: 2004/0006007 (2004-01-01), Gosselin et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2004/0067901 (2004-04-01), Bhat et al.
patent: 2004/0229776 (2004-11-01), Chen et al.
patent: 2004/0229818 (2004-11-01), Llinas-Brunet et al.
patent: 2004/0254159 (2004-12-01), Hasvold et al.
patent: 2004/0266668 (2004-12-01), Nakajima et al.
patent: 2005/0020503 (2005-01-01), Llinas-Brunet et al.
patent: 2005/0038240 (2005-02-01), Connolly et al.
patent: 2006/0257980 (2006-11-01), Li
patent: 2007/0027071 (2007-02-01), Holloway et al.
patent: 2010/0099695 (2010-04-01), Liverton et al.
patent: 1719773 (2006-11-01), None
patent: 2337262 (1999-11-01), None
patent: 2430621 (2007-04-01), None
patent: 97/41211 (1997-11-01), None
patent: 98/22496 (1998-05-01), None
patent: 98/46630 (1998-10-01), None
patent: 99/07733 (1999-02-01), None
patent: 99/07734 (1999-02-01), None
patent: 99/38888 (1999-08-01), None
patent: 99/43691 (1999-09-01), None
patent: 99/50230 (1999-10-01), None
patent: 99/64442 (1999-12-01), None
patent: 00/09543 (2000-02-01), None
patent: 00/09546 (2000-02-01), None
patent: 00/25780 (2000-05-01), None
patent: 00/59929 (2000-10-01), None
patent: 01/00622 (2001-01-01), None
patent: 01/47883 (2001-07-01), None
patent: 01/60379 (2001-08-01), None
patent: 01/68663 (2001-09-01), None
patent: 01/77091 (2001-10-01), None
patent: 01/77113 (2001-10-01), None
patent: 01/79246 (2001-10-01), None
patent: 01/90121 (2001-11-01), None
patent: 01/92282 (2001-12-01), None
patent: 02/04425 (2002-01-01), None
patent: 02/06246 (2002-01-01), None
patent: 02/18404 (2002-03-01), None
patent: 02/20497 (2002-03-01), None
patent: 02/32920 (2002-04-01), None
patent: 02/48116 (2002-06-01), None
patent: 02/48165 (2002-06-01), None
patent: 02/48172 (2002-06-01), None
patent: 02/051425 (2002-07-01), None
patent: 02/057287 (2002-07-01), None
patent: 02/057425 (2002-07-01), None
patent: 02/100415 (2002-12-01), None
patent: 03/015755 (2003-02-01), None
patent: 03/026589 (2003-04-01), None
patent: 03/026675 (2003-04-01), None
patent: 03/062192 (2003-07-01), None
patent: 03/062211 (2003-07-01), None
patent: 03/064455 (2003-08-01), None
patent: 03/068244 (2003-08-01), None
patent: 03/093290 (2003-11-01), None
patent: 03/099274 (2003-12-01), None
patent: 2004/000858 (2003-12-01), None
patent: 2004/002422 (2004-01-01), None
patent: 2004/002999 (2004-01-01), None
patent: 2004/003000 (2004-01-01), None
patent: 2004/003138 (2004-01-01), None
patent: 2004/007512 (2004-01-01), None
patent: 2004/011478 (2004-02-01), None
patent: 2004/013300 (2004-02-01), None
patent: 2004/028481 (2004-04-01), None
patent: 2004/041201 (2004-05-01), None
patent: 2004/087714 (2004-10-01), None
patent: 2004/093915 (2004-11-01), None
patent: 2004/103996 (2004-12-01), None
patent: 2004/110442 (2004-12-01), None
patent: 2005/003147 (2005-01-01), None
patent: 2005/016927 (2005-02-01), None
patent: 2005/023819 (2005-03-01), None
patent: 2005/034941 (2005-04-01), None
patent: 2005/046712 (2005-05-01), None
patent: 2005/070955 (2005-08-01), None
patent: 2005/080399 (2005-09-01), None
patent: 2006/008556 (2006-01-01), None
patent: 2006/020082 (2006-02-01), None
patent: 2006/021341 (2006-03-01), None
patent: 2006/027628 (2006-03-01), None
patent: 2006/029912 (2006-03-01), None
patent: 2006/046030 (2006-05-01), None
patent: 2006/046039 (2006-05-01), None
patent: 2006/119061 (2006-11-01), None
patent: 2006/119975 (2006-11-01), None
patent: 2007/015787 (2007-02-01), None
patent: 2007/015855 (2007-02-01), None
patent: 2007/016441 (2007-02-01), None
patent: 2007/028789 (2007-03-01), None
patent: 2007/029029 (2007-03-01), None
patent: 2007/131966 (2007-11-01), None
patent: 2007/145894 (2007-12-01), None
patent: 2007/148135 (2007-12-01), None
patent: 2008/002924 (2008-01-01), None
patent: 2008/051475 (2008-05-01), None
patent: 2008/051477 (2008-05-01), None
patent: 2008/051514 (2008-05-01), None
patent: 2008/057028 (2008-05-01), None
patent: 2008/057208 (2008-05-01), None
patent: 2008/057209 (2008-05-01), None
patent: 2008/112108 (2008-09-01), None
patent: 2009/005687 (2009-01-01), None
patent: 2009/010804 (2009-01-01), None
patent: 2009/064955 (2009-05-01), None
patent: 2009/064975 (2009-05-01), None
patent: 2010/011566 (2010-01-01), None
Youwei Yan et al., Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Angstrom resolution structure in a hexagonal crystal form, 7 Protein Science 837 (1998).
Brian W. Dymock et al., “Novel Approaches to the Treatment of Hepatitis C Virus Infection,” 11 Antiviral Chemistry & Chemotherapy 79-96 (2000).
Hugo R. Rosen & David R. Gretch, “Hepatitis C virus: current understanding and prospects for future therapies,” 5 Molec. Med. Today 393-99 (1999).
Darius Moradpour & Hubert E. Blum, “Current and evolving therapies for hepatitis C,” 11 Euro. J. Gastroenterol. Hepatol. 1189-1202 (1999).
Ralf Bartenschlager, “Candidate Targets for Hepatitis C Virus-Specific Antiviral Therapy,” 40(5-6) Intervirology 378-93 (1997).
Georg M. Lauer & Bruce D. Walker, “Hepatitis C Virus Infection,” 345(1) N. Engl. J. Med. 41-52 (2001); correction: 345 (19) N. Engl. J. Med. 1425-26 (2001).
Brain W. Dymock, “Emerging therapies for hepatitis C virus infection,” 6 Emerging Drugs 13-42 (2001).
Charlene Crabb, Infectious Diseases. “Hard-Won Advances Spark Excitement about Hepatitis C,” Science 506-507 (2001).
Rogers E. Harry-O'Kuru et al., “A Short, Flexible Route toward 2'-C-Branched Ribonucleosides,” 62 J. Org. Chem. 1754-59 (1997).
Michael S. Wolfe & Rogers E. Harry-O'Kuru, “A Concise Synthesis of 2'-C-Methylribonucleosides,” 36(42) Tetrahedron Letters 7611-14 (1995).
Scott J. Miller et al., “Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides,” 118 J. Am. Chem. Soc. 9606-14 (1996).
Jason S. Kingsbury et al., “A Recyclable Ru-Based Metathesis Catalyst,” 121 J. Am. Chem. Soc. 791-99 (1999).
Matthias Scholl et al., “Synthesis and Activity of a New Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 1,3-Dimesityl-4,5-dihydroimidazol-2-ylidene Ligands,” 1(6) Organic Letters 953-56 (1999).
Alois Furstner et al., “Total Synthesis and Structural Refinement of the Cyclic Tripyrrole Pigment Nonylprodigiosin,” 64 J. Org. Chem. 8275-80 (1999).
Tina M. Trnka & Robert H. Grubbs, “The Development of L2X2R-CHR Olefin Metathesis Catalysts: An Organometallic Success Story,” 34 Acc. Chem. Res. 18-29 (2001).
A. Srikrishna et al., “Enantiospecific Construction of the BC-ring System of Taxanes,” 45 Tetrahedron Letters 2939-42 (2004).
Yung-Son Hon et al., “Dibromomethane as one-carbon source in organic synthesis: a versatile methodology to prepare the cyclic and acyclic alpha-methylene or alpha-keto acid derivatives from the corresponding terminal alkenes,” 60 Tetrahedron 4837-60 (2004).
Eusebio Juaristi & Hugo A. Jimenez-Vazquez, “Single Electron Transfer Mechanism in the Reaction of 1,3-Dithianyllithium and Alkyl Iodides,” 56 J. Org. Chem. 1623-30 (1991).
Paola Conti et al., “Chemoenzymatic Synthesis of the Enantiomers of Desoxymuscarine,” 9 Tetrahedron: Asymmetry 657-65 (1998).
Robert M. Coates & Mark W. Johnson, “Stereoselective Synthesis of Moenocinol and Ass

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Macrocyclic quinoxaline compounds as HCV NS3 protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic quinoxaline compounds as HCV NS3 protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic quinoxaline compounds as HCV NS3 protease... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2640573

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.